These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28430399)

  • 1. Targeting Conformational Activation of CDK2 Kinase.
    Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
    Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
    Prével C; Kurzawa L; Van TN; Morris MC
    Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
    Premnath PN; Craig SN; Liu S; McInnes C
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3754-60. PubMed ID: 27297568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing an Allosteric Pocket of CDK2 with Small Molecules.
    Christodoulou MS; Caporuscio F; Restelli V; Carlino L; Cannazza G; Costanzi E; Citti C; Lo Presti L; Pisani P; Battistutta R; Broggini M; Passarella D; Rastelli G
    ChemMedChem; 2017 Jan; 12(1):33-41. PubMed ID: 27860401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
    Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
    Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
    Mou J; Chen D; Deng Y
    Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational Equilibrium of CDK/Cyclin Complexes by Molecular Dynamics with Excited Normal Modes.
    Floquet N; Costa MG; Batista PR; Renault P; Bisch PM; Raussin F; Martinez J; Morris MC; Perahia D
    Biophys J; 2015 Sep; 109(6):1179-89. PubMed ID: 26255588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II Inhibitors Targeting CDK2.
    Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
    ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network-based modelling and percolation analysis of conformational dynamics and activation in the CDK2 and CDK4 proteins: dynamic and energetic polarization of the kinase lobes may determine divergence of the regulatory mechanisms.
    Verkhivker GM
    Mol Biosyst; 2017 Oct; 13(11):2235-2253. PubMed ID: 28926061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
    Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
    Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
    Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
    Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice.
    Faber EB; Wang N; John K; Sun L; Wong HL; Burban D; Francis R; Tian D; Hong KH; Yang A; Wang L; Elsaid M; Khalid H; Levinson NM; Schönbrunn E; Hawkinson JE; Georg GI
    J Med Chem; 2023 Feb; 66(3):1928-1940. PubMed ID: 36701569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
    Talapati SR; Goyal M; Nataraj V; Pothuganti M; R SM; Gore S; Ramachandra M; Antony T; More SS; Rao NK
    Chem Biol Drug Des; 2021 Nov; 98(5):857-868. PubMed ID: 34423559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
    Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
    Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.
    Coxon CR; Anscombe E; Harnor SJ; Martin MP; Carbain B; Golding BT; Hardcastle IR; Harlow LK; Korolchuk S; Matheson CJ; Newell DR; Noble ME; Sivaprakasam M; Tudhope SJ; Turner DM; Wang LZ; Wedge SR; Wong C; Griffin RJ; Endicott JA; Cano C
    J Med Chem; 2017 Mar; 60(5):1746-1767. PubMed ID: 28005359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
    Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
    Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.